CAS: 182198-35-2; 4-Chloro-5-Phenylthieno[2,3-D]Pyrimidine

该化合物是一种七环化合物,其基芯在4位置被氯组取代,在5位置被一个苯环取代.这一结构具有重要的回动性,使其成为制药和农用化学合成的宝贵中间体.该组加强了其作为多种替代核生殖反应的电极的实用性,能够进一步实现功能化.其僵硬的芳香框架有助于稳定性和潜在的生物活动,特别是在药用化学应用中,例如活性抑制剂的开发.该组具有明确界定的晶状特性,有利于净化和定性,确保研究和工业环境中的再生性.其合成无障碍性和模块再活性使该组成为建造复杂的分子结构的首选建筑块.

结构式图片

相似化合物

331761-46-7 374104-63-9 76872-27-0

欧盟法规

C&L通报

上下游产品

pyrimidine-4(3H)one5-phenylthieno2,3-dpyrimidine-4(3H)one ethyl 2-amino-4-phenyl-thiophene-3-carboxylate H-thieno[2,3-d]pyrimidin-4-one5-phenyl-3H-thieno[2,3-d]pyrimidin-4-one acetophenone 2-(5-Phenyl-thieno[2,3-d]pyrimidin-4-ylamino)-ethanol pyrimidine4-Hydrazino-5-phenylthieno2,3-dpyrimidine 5-Phenyl-thieno[2,3-d]pyrimidine-4-thiol thienopyrimidine9-Phenyl-1,2,4-triazolo4,3-cthieno3,2-epyrimidine

合成工艺路线路线简述

  • 合成目标产物 4-Chloro-5-Phenylthieno[2,3-D]Pyrimidine 主要起始原料 7-Phenyl-9-Thia-2,4-Diazabicyclo[4.3.0]Nona-2,7,10-Trien-5-One
  • (文献来源)合成步骤主要原料 7-Phenyl-9-Thia-2,4-Diazabicyclo[4.3.0]Nona-2,7,10-Trien-5-One
📜2-(1-苯基亚乙基)丙二腈置于碳酸氢钠,Sulfur,三氯氧磷体系中,用 四氢呋喃,水 用作溶剂,化学反应 10.0H,反应生成4-氯-5-苯基噻酚[2,3-D]嘧啶
参考文献:一类多取代喹诺酮类化合物及其制备方法和用途
标题:一类多取代喹诺酮类化合物及其制备方法和用途
摘要:本发明提供了一类多取代喹诺酮类化合物及其制备方法和用途,具体地,本发明提供了一种如下式ⅰ所示的多取代喹诺酮化合物,其光学异构体,及药学上可接受的盐或溶剂合物,其中各基团的定义如说明书中所述.本发明的喹诺酮化合物具有非常好的c-Met抑制活性,可以用于c-Met活性或表达量相关疾病的治疗.

海关参考信息

专利信息


专利号:US-2004138238-A1
优先权日:2002-08-08
标题 :Substituted aminopyrimidine compounds as neurokinin antagonists
发明人:DHANOA DALE S; BECKER OREN; NOIMAN SILVIA; KESAVAN VENKITASAMY; SHARADENDU ANURAG; MOHANTY PRADYUMNA; CHEN DONGLI; CHERUKU SRINIVASA RAO; HEIFETZ ALEXANDER; KALID ORI; MARANTZ YAEL; NUDELMAN RAPHAEL; SBACHAM SHARON; BAR-HAIM SHAY
摘要:The invention discloses tachykinin receptor antagonists. The tachykinin family of receptors comprising the neurokinins substance P (SP), neurokinin A, and neurokinin B and related neuropeptides that are widely distributed in the peripheral and central nervous system. The invention discloses novel aminopyrimidine derivatives, synthesis and uses thereof for the treatment of diseases mediated directly or indirectly by the tachykinin receptors. These diseases include central nervous system disorders such as anxiety, pain, depression, emesis, in particular cancer chemotherapy induced emesis, respiratory and inflammatory bowel disease and other gastric disorders, asthma, schizophrenia, ophthalmic diseases such as glaucoma, ocular hypotension, neural injury, stroke, cardiac disorders, psoriasis, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

合成参考文献


参考文献:10.1016/j.jbc.2022.102228
摘要:Scoles DR, Gandelman M, Paul S, Dexheimer T, Dansithong W, Figueroa KP, Pflieger LT, Redlin S, Kales SC, Sun H, Maloney D, Damoiseaux R, Henderson MJ, Simeonov A, Jadhav A, Pulst SM. A quantitative high-throughput screen identifies compounds that lower expression of the SCA2-and ALS-associated gene ATXN2. Journal of Biological Chemistry. 2022 Aug;298(8):102228. doi: 10.1016/j.jbc.2022.102228.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知